ICATT | Jotup

eTrueNorth and Hy-Vee, Inc. Partner to Offer Pharmacy-Based COVID-19 and Flu Test and Treat

Retrieved on:

Thursday, March 23, 2023

Infection, Partnership, University, U.S. Department of Defense Strategy for Operating in Cyberspace, HHS, HIV, Washington State University, Pharmacy, Cholesterol, Office of Inspector General, U.S. Department of Health and Human Services, COVID-19, Hepatitis C, CDC, RSV, ICATT, Pharmaceutical industry, Sand, Vaccine

The newly available diagnostic test detects active COVID-19 and/or flu infection, with results available in as few as 30 minutes.

Key Points:

The newly available diagnostic test detects active COVID-19 and/or flu infection, with results available in as few as 30 minutes.
Together, these two companies bring the test to treat service to a first wave of nine Hy-Vee pharmacies throughout Iowa until April 30, 2023.
"Rapid combination test results coupled with pharmacist-prescribed treatment at community pharmacies are solutions eTrueNorth is supporting for our pharmacy partners."
Part of the eTrueNorth mission is to increase the availability of point of care testing which offer results during the same visit.

Color Health Partners with CDC to Increase Equitable Access to COVID-19 Testing

Retrieved on:

Friday, July 8, 2022

BURLINGAME, Calif., July 8, 2022 /PRNewswire/ -- Color Health, a health technology company committed to advancing public health, is providing free COVID-19 testing through the U.S. Centers for Disease Control and Prevention's Increasing Community Access to Testing (ICATT) program, to help millions of Americans in underserved communities access no-cost COVID-19 testing.

Key Points:

BURLINGAME, Calif., July 8, 2022 /PRNewswire/ -- Color Health, a health technology company committed to advancing public health, is providing free COVID-19 testing through the U.S. Centers for Disease Control and Prevention's Increasing Community Access to Testing (ICATT) program, to help millions of Americans in underserved communities access no-cost COVID-19 testing.
"Through the ICATT program, we're bringing Color's proven testing capabilities and our commitment to improving public health to locations where they are urgently needed.
Testing at these sites will be:
No cost Regardless of insurance status, individuals will not be charged for testing at a Color site.
For those interested in becoming an approved testing site to support the CDC's Increasing Community Access to Testing Program (ICATT) alongside Color, you can enter your information here .

Previon Steps up to Help Americans Get Easy Access to COVID-19 Test Kits

Retrieved on:

Friday, February 11, 2022

Previon today announced its role in important initiatives designed to meet demand for COVID-19 tests and services.

Key Points:

Previon today announced its role in important initiatives designed to meet demand for COVID-19 tests and services.
Airline passengers have the option to purchase these specially discounted test kits before or after purchasing their airline tickets.
For example, Previon prints a barcode on each test kit, thus associating the test kit with the specific person to whom it was sent.
Previon is assembling hundreds of thousands of these test kits and shipping them to retailers.

eTrueNorth is Actively Recruiting Retail Pharmacies to Participate in its INeedaCOVID19Test.com Laboratory-based PCR COVID-19 Testing Program

Retrieved on:

Tuesday, December 14, 2021

Participating pharmacies will be able to offer free COVID-19 testing in their local communities and receive reimbursement.

Key Points:

Participating pharmacies will be able to offer free COVID-19 testing in their local communities and receive reimbursement.
Pharmacies that are not currently offering COVID-19 testing services billed through public or private insurance will receive reimbursement from the ICATT program on a per-resulted test basis.
Participating pharmacies will be part of the current Federally-funded effort to expand testing to more than 15,000 pharmacy locations across the country.
In April 2020, eTrueNorth began its participation in the drive-through COVID-19 testing program in partnership with the U.S. Department of Health & Human Services.

Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program

Retrieved on:

Thursday, August 26, 2021

State, Local, Other Education, Other Health, Healthcare Reform, Primary, Secondary, Pharmaceutical, Education, General Health, Medical Devices, Infectious Diseases, Public Policy, Government, Science, Biotechnology, Other Science, Health, Monotonic function, Urology, Program, ELC, Parent, Human services, Digital, Student, Family, Point-of-care testing, United States Department of Health and Human Services, HHS, Science, Government, Rite Aid, Travel, RAD, Hospital, NYSE, Learning, Office of Inspector General, U.S. Department of Health and Human Services, OPKO Health, Aid, NASDAQ, RT, Environment, Patient, Solution, National Association Medical Staff Services, Genetics, Pharmacy, School, COVID-19, ICATT, Pharmaceutical industry, Tutoring, BioReference Laboratories, Inc., Rite Aid Corporation, BIOREFERENCE LABORATORIES, INC., RITE AID CORPORATION

Testing appointments will become available prior to the start of the school year, and individuals are required to pre-register and schedule a time slot for testing at bioreferencelabs.bioreference.com/nyschooltesting .

Key Points:

Testing appointments will become available prior to the start of the school year, and individuals are required to pre-register and schedule a time slot for testing at bioreferencelabs.bioreference.com/nyschooltesting .
COVID-19 testing is voluntary and will be provided at no cost to the students family or to the school district for this program.
We are proud to partner with the U.S. Department of Health and Human Services, BioReference and Rite Aid on this important initiative.
BioReference is proud to continue supporting New York States active surveillance programs with this Back to School testing program, said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories.